Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics

Novogene is a leading provider of genomic services and solutions offering extensive next generation sequencing (NGS) capacity and bioinformatics expertise....

November 06, 2023 | Monday | News
Singapore's Engine Biosciences Secures $27M in Series A Extension for Precision Oncology Development and Biomarker Research

Funds to support translation of R&D programs derived from proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial gen...

November 02, 2023 | Thursday | News
Merck Expands Oncology Portfolio with Hengrui Partnership, Promises More Treatment Options for Difficult-to-Treat Cancers

Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...

October 31, 2023 | Tuesday | News
LianBio Reports Phase 3 LIBRA Trial Results for TP-03 in Chinese Demodex Blepharitis

The co-primary endpoints of the LIBRA trial were mite eradication (mite density of 0 mites per lash) and complete collarette cure (collarette score of 0) a...

October 31, 2023 | Tuesday | News
Coherus and Junshi Biosciences Secure FDA Approval for LOQTORZI™ in All NPC Treatment Lines

Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing ...

October 30, 2023 | Monday | News
Data and AI in Life Sciences: Shaping the Future - An Exclusive Interview with Mr. Shakthi Nagappan, CEO of Telangana Life Sciences

In a rapidly evolving world where data and artificial intelligence have become paramount, BioAsia 2024 presents a theme that transcends traditional boundar...

October 27, 2023 | Friday | Interaction
AI-Powered Immune Phenotyping by Lunit SCOPE IO Marks First TKI-Resistant Lung Cancer Immunotherapy Success

Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mut...

October 25, 2023 | Wednesday | News
Astellas and Seagen Report Positive Results for PADCEV® Combination in Urothelial Cancer Study

– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...

October 23, 2023 | Monday | News
Thermo Fisher Partners with Boehringer Ingelheim on Companion Diagnostic for NSCLC Treatment

To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targete...

October 20, 2023 | Friday | News
ERS Genomics completes licensing agreement with Syngene International

ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International, India's leading Contract Research, Development and Manufacturing Org...

October 19, 2023 | Thursday | News
Malaysia Healthcare Travel Council Announces New Chief Executive Officer

Dr. Ali will be spearheading all aspects of MHTC’s operations, ensuring its commitment to facilitating and promoting the nation’s healthcare tr...

October 17, 2023 | Tuesday | News
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...

October 16, 2023 | Monday | News
FDA Approves Etrasimod by Pfizer for Severe Ulcerative Colitis

Everest Medicines  announced  that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administratio...

October 16, 2023 | Monday | News
MHTC and Experts Unite to Spotlight Breast Cancer Awareness

In conjunction with breast cancer awareness month, the Malaysia Healthcare Travel Council (MHTC) together with Subang Jaya Medical Centre, organised a thou...

October 16, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close